DE69426569D1 - Bivalente thrombininhibitore - Google Patents

Bivalente thrombininhibitore

Info

Publication number: DE69426569D1
Authority: DE; Germany
Prior art keywords: thrombin; glu; inhibitors; pct; active site
Prior art date: 1993-10-25
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

DE69426569T

Other languages

English (en)

Other versions

DE69426569T2 (de

Inventor

Yasuo Konishi

Zbigniew Szewczuk

Yuko Tsuda

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

National Research Council of Canada

Original Assignee

National Research Council of Canada

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-25

Filing date

1994-10-25

Publication date

2001-02-15

1993-10-25 Priority claimed from GB9321951A external-priority patent/GB9321951D0/en

1994-10-25 Application filed by National Research Council of Canada filed Critical National Research Council of Canada

2001-02-15 Application granted granted Critical

2001-02-15 Publication of DE69426569D1 publication Critical patent/DE69426569D1/de

2001-05-10 Publication of DE69426569T2 publication Critical patent/DE69426569T2/de

2014-10-26 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title abstract 5
108090000190 Thrombin Proteins 0.000 abstract 3
229940122388 Thrombin inhibitor Drugs 0.000 abstract 3
229960004072 thrombin Drugs 0.000 abstract 3
239000003868 thrombin inhibitor Substances 0.000 abstract 3
239000000758 substrate Substances 0.000 abstract 2
241000237902 Hirudo medicinalis Species 0.000 abstract 1
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 abstract 1
238000010494 dissociation reaction Methods 0.000 abstract 1
230000005593 dissociations Effects 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical group C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 1
238000000338 in vitro Methods 0.000 abstract 1
238000001727 in vivo Methods 0.000 abstract 1
238000010348 incorporation Methods 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
PBLZLIFKVPJDCO-UHFFFAOYSA-N omega-Aminododecanoic acid Natural products NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
230000002797 proteolythic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DE69426569T 1993-10-25 1994-10-25 Bivalente thrombininhibitore Expired - Fee Related DE69426569T2 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GB9321951A GB9321951D0 (de)	1993-10-25	1993-10-25
GB9412707A GB9412707D0 (de)	1993-10-25	1994-06-24
PCT/CA1994/000585 WO1995011921A1 (en)	1993-10-25	1994-10-25	Bivalent thrombin inhibitors

Publications (2)

Publication Number	Publication Date
DE69426569D1 true DE69426569D1 (de)	2001-02-15
DE69426569T2 DE69426569T2 (de)	2001-05-10

Family

ID=26303742

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69426569T Expired - Fee Related DE69426569T2 (de)	1993-10-25	1994-10-25	Bivalente thrombininhibitore

Country Status (8)

Country	Link
US (1)	US6127337A (de)
EP (1)	EP0725797B1 (de)
AT (1)	ATE198603T1 (de)
AU (1)	AU7935494A (de)
CA (1)	CA2175388A1 (de)
DE (1)	DE69426569T2 (de)
ES (1)	ES2153433T3 (de)
WO (1)	WO1995011921A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU761011B2 (en) *	1997-10-15	2003-05-29	National Research Council Of Canada	Trivalent thrombin inhibitor
US7829085B2 (en) *	1999-07-14	2010-11-09	Life Sciences Research Partners Vzw	Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
EP1278549B1 (de)	2000-05-02	2008-12-10	Theravance, Inc.	Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
EP1706079B1 (de)	2003-08-14	2013-02-20	ThromboGenics N.V.	Antikörper gegen faktor viii mit modifizierter glykosilierung in der variablen region
ATE510013T1 (de) *	2004-06-23	2011-06-15	Ca Nat Research Council	Verfahren und verwendungen von linker enthaltenden polypeptidliganden
US7915223B2 (en) *	2004-09-27	2011-03-29	Technion Research & Development Foundation Ltd.	Antimicrobial agents
MX2007003608A (es) *	2004-09-27	2007-08-14	Technion Res & Dev Foundation	Agentes antimicrobianos novedosos.
USRE46830E1 (en)	2004-10-19	2018-05-08	Polypeptide Laboratories Holding (Ppl) Ab	Method for solid phase peptide synthesis
EP2142257A2 (de) *	2007-04-30	2010-01-13	Technion Research & Development Foundation Ltd.	Polymer-mittel gegen krebs
US20080269065A1 (en) *	2007-04-30	2008-10-30	Syntrix Biosystems, Inc.	Conformationally Constrained Analytical Probes
EP2152289A1 (de) *	2007-04-30	2010-02-17	Technion Research & Development Foundation Ltd.	Neue antimikrobielle mittel
GB0711779D0 (en)	2007-06-18	2007-07-25	Univ Singapore	Thrombin inhibitor
US20100203001A1 (en) *	2007-07-11	2010-08-12	Aplagen Gmbh	Process for forming disulfide bridges
EP2346526A2 (de)	2008-09-22	2011-07-27	Massachusetts Institute of Technology	Zusammensetzungen und verfahren zur verwendung von liganden-dimeren
US9029328B2 (en)	2010-03-24	2015-05-12	The Brigham And Women's Hospital, Inc.	Methods for cardioprotection and cardioregeneration with dimers of EGF family ligands

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3978045A (en) *	1973-08-13	1976-08-31	Mitsubishi Chemical Industries Ltd.	N2 -dansyl-L-arginine derivatives, and the pharmaceutically acceptable acid addition salts thereof
US4173630A (en) *	1974-11-08	1979-11-06	Mitsubishi Chemical Industries Limited	N2 Arylsulfonyl-L-argininamides and the pharmaceutically acceptable salts thereof
US5196404B1 (en) *	1989-08-18	1996-09-10	Biogen Inc	Inhibitors of thrombin
WO1991019734A2 (en) *	1990-06-15	1991-12-26	Majesty (Her) In Right Of Canada As Represented By The National Research Council Of Canada	Thrombin inhibitors based on the amino acid sequence of hirudin
GB9209032D0 (en) *	1992-04-25	1992-06-10	Ciba Geigy Ag	New peptide derivatives

1994
- 1994-10-25 WO PCT/CA1994/000585 patent/WO1995011921A1/en active IP Right Grant
- 1994-10-25 EP EP94930133A patent/EP0725797B1/de not_active Expired - Lifetime
- 1994-10-25 AT AT94930133T patent/ATE198603T1/de not_active IP Right Cessation
- 1994-10-25 ES ES94930133T patent/ES2153433T3/es not_active Expired - Lifetime
- 1994-10-25 DE DE69426569T patent/DE69426569T2/de not_active Expired - Fee Related
- 1994-10-25 AU AU79354/94A patent/AU7935494A/en not_active Abandoned
- 1994-10-25 CA CA002175388A patent/CA2175388A1/en not_active Abandoned
- 1994-10-25 US US08/636,698 patent/US6127337A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69426569T2 (de)	2001-05-10
EP0725797A1 (de)	1996-08-14
ATE198603T1 (de)	2001-01-15
AU7935494A (en)	1995-05-22
WO1995011921A1 (en)	1995-05-04
EP0725797B1 (de)	2001-01-10
US6127337A (en)	2000-10-03
CA2175388A1 (en)	1995-05-04
ES2153433T3 (es)	2001-03-01

Publication	Publication Date	Title
DE69426569D1 (de)	2001-02-15	Bivalente thrombininhibitore
IL109016A (en)	2005-07-25	Purified soluble vascular endothelial cell growth factor (vegf) inhibitor encoding purified dna, a process for its preparation and pharmaceutical compositions comprising it
ATE184022T1 (de)	1999-09-15	Neuropeptide y antagoniste
DE60117781D1 (de)	2006-05-04	Peptidderivate des apolipoproteins-a1/aii
ATE171712T1 (de)	1998-10-15	Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
WO2001005810A3 (de)	2001-05-17	CYCLISCHE PEPTIDDERIVATE ALS INHIBITOREN DES INTEGRINS αvβ¿6?
DE69434070D1 (de)	2004-11-18	Kininogen-inhibitoren
SG129211A1 (en)	2007-02-26	Therapeutic molecules
FI956055A0 (fi)	1995-12-15	Tekijä VII:sta johdettuja peptidejä
DE69429062D1 (de)	2001-12-20	Thrombin-inhibitoren
DE60031422D1 (de)	2006-11-30	Peptidanaloge als selektive inhibitoren der thrombinaktivierung des durch protease aktivierten rezeptors
DE69615185D1 (de)	2001-10-18	Faktor ix bindende peptide abgeleitet von faktor vii und ihre verwendung als inhibitoren der blutgerinnung
ATE146526T1 (de)	1997-01-15	Neues thrombininhibitorisches protein aus zecken
TW340849B (en)	1998-09-21	Novel cyclopeptides and pharmaceutical compositions as integrin inhibitors comprizing the same
NO924925D0 (no)	1992-12-18	Bradykinin-antagonister for behandling av akutt betennelse i bukspyttkjertelen
Murakami et al.	1989	A cytocidal tissue kallikrein isolated from mouse submandibular glands
Preissner	1990	The Molecular Anatomy of Vitronectin as Extracellular Regulator Protein: Multifunctional Properties of the Heparin-Binding Domain
MX9605037A (es)	1998-02-28	Inhibidores de factor xa.
GR850626B (de)	1985-07-11

Legal Events

Date	Code	Title	Description
2002-02-07	8364	No opposition during term of opposition
2004-08-26	8339	Ceased/non-payment of the annual fee